These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 9377299)

  • 1. [Association of plasmapheresis and high doses of intravenous immunoglobulins in the treatment of myasthenia gravis].
    Tatay J; Díez-Tejedor E; Frank A; Tejada J; Marrero C; Barreiro P
    Rev Neurol; 1997 Sep; 25(145):1402-6. PubMed ID: 9377299
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical trial of plasma exchange and high-dose intravenous immunoglobulin in myasthenia gravis. Myasthenia Gravis Clinical Study Group.
    Gajdos P; Chevret S; Clair B; Tranchant C; Chastang C
    Ann Neurol; 1997 Jun; 41(6):789-96. PubMed ID: 9189040
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Myasthenia gravis: effect of immunoactive therapies.
    Fornádi L; Horváth R; Bárdosi Z; Szobor A
    Acta Med Hung; 1994; 50(1-2):83-92. PubMed ID: 7638045
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High-dose intravenous immunoglobulin for the treatment of MuSK antibody-positive seronegative myasthenia gravis.
    Takahashi H; Kawaguchi N; Nemoto Y; Hattori T
    J Neurol Sci; 2006 Sep; 247(2):239-41. PubMed ID: 16876198
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Plasmapheresis or intravenous immunoglobulin for myasthenia gravis crisis in King Chulalongkorn Memorial Hospital.
    Pittayanon R; Treeprasertsuk S; Phanthumchinda K
    J Med Assoc Thai; 2009 Apr; 92(4):478-82. PubMed ID: 19374297
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Treatment of myasthenia gravis with intravenous immunoglobulin G (IVIG)].
    Lavrnić DB; Stojanović V; Marinković Z; Pavlović S; Vidaković A; Apostolski S
    Srp Arh Celok Lek; 1995; 123(5-6):146-8. PubMed ID: 17974459
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative analysis of therapeutic options used for myasthenia gravis.
    Mandawat A; Kaminski HJ; Cutter G; Katirji B; Alshekhlee A
    Ann Neurol; 2010 Dec; 68(6):797-805. PubMed ID: 21061395
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predictors of response to immunomodulation in patients with myasthenia gravis.
    Katzberg HD; Barnett C; Bril V
    Muscle Nerve; 2012 May; 45(5):648-52. PubMed ID: 22499090
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The treatment of severe forms of myasthenia gravis.
    Iani C; Caramia M; Morosetti M; Loberti M; Palmieri MG; Meloni C; Gallucci MT; Casciani CU; Bernardi G
    Funct Neurol; 1998; 13(3):231-7. PubMed ID: 9800150
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Intensive care in myasthenic and cholinergic crises].
    Popova LM; Piradov MA
    Anesteziol Reanimatol; 1996; (2):13-5. PubMed ID: 8754165
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Plasmapheresis does not affect polysomnographic parameters in patients with myasthenia gravis: a case series study.
    Yeh JH; Chen WH; Chiu HC; Lee CT; Hsu CY
    Artif Organs; 2010 Jun; 34(6):E200-3. PubMed ID: 20456321
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Surgical outcome in thymic tumors with myasthenia gravis after plasmapheresis--a comparative study.
    Sarkar BK; Sengupta P; Sarkar UN
    Interact Cardiovasc Thorac Surg; 2008 Dec; 7(6):1007-10. PubMed ID: 18682429
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Plasmapheresis, a safe treatment when applied to the correct indication and with awareness of the complications].
    Pruijm MT; Vogt B; Cherpillod A; Burnier M
    Ned Tijdschr Geneeskd; 2008 Oct; 152(42):2261-6. PubMed ID: 19009872
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Use of therapeutic plasmapheresis in patients with generalized myasthenia during exacerbations in the late period following thymectomy].
    Marchuk AI; Golovteev VV; Sapin SM; Shagal DI
    Zh Nevropatol Psikhiatr Im S S Korsakova; 1986; 86(3):330-3. PubMed ID: 3705836
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [A comparative study of intravenous immunoglobulin and plasmapheresis preoperatively in myasthenia].
    Pérez Nellar J; Domínguez AM; Llorens-Figueroa JA; Ferrá-Betancourt A; Pardo A; Quiala M; Gali Z
    Rev Neurol; 2001 Sep 1-15; 33(5):413-6. PubMed ID: 11727205
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Plasmapheresis in patients with myasthenia gravis].
    Konishi T
    Nihon Rinsho; 2008 Jun; 66(6):1165-71. PubMed ID: 18540364
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Long-term treatment with 7S immunoglobulins in myasthenia gravis. Preliminary clinical results].
    Bamberg C; Janzen RW; Szabados M
    Nervenarzt; 1996 Apr; 67(4):327-32. PubMed ID: 8684513
    [TBL] [Abstract][Full Text] [Related]  

  • 18. IV immunoglobulin in patients with myasthenia gravis: a randomized controlled trial.
    Zinman L; Ng E; Bril V
    Neurology; 2007 Mar; 68(11):837-41. PubMed ID: 17353471
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The use of intravenous immunoglobulin in the treatment of autoimmune neuromuscular diseases: evidence-based indications and safety profile.
    Dalakas MC
    Pharmacol Ther; 2004 Jun; 102(3):177-93. PubMed ID: 15246245
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapeutic options in autoimmune myasthenia gravis.
    García-Carrasco M; Escárcega RO; Fuentes-Alexandro S; Riebeling C; Cervera R
    Autoimmun Rev; 2007 Jun; 6(6):373-8. PubMed ID: 17537383
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.